ArticleMedicine2026
Trends and cross-country inequalities in the global burden of thyroid cancer, 1990-2021: A population-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo evaluate the trends in the burden of thyroid cancer (TC) over the past 30 years, assess inequalities between countries, and predict changes by 2045.
methodsTC incidence, prevalence, deaths, and disability-adjusted life years (DALYs), with 95% uncertainty intervals (UIs), were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021. We analyzed global, regional, and national trends during 1990-2021. Decomposition analysis assessed population growth, aging, and epidemiological change. Health inequalities were quantified using World Health Organization-recommended methods, and burden was projected to 2045.
resultsIn 2021, estimates were 249,538 (95% UI: 223,290-274,638) incident cases, 1,987,148 (1,776,275-2,198,245) prevalent cases, 44,799 (39,925-48,541) deaths, and 1,246,485 (1,094,416-1,375,853) DALYs globally. East Asia had the most cases, whereas high-income North America had the highest age-standardized rate (ASR). During 1990 to 2021, TC burden increased, with incidence, prevalence, and deaths rising fastest during 2000 to 2010. Females (53.51%) and middle-Socio-demographic Index (SDI) regions (41.69%) accounted for the largest DALY proportions. DALY changes were driven mainly by population growth, followed by aging. SDI-related inequalities increased: the incidence gap between the highest- and lowest-SDI countries rose from 2.63 (95% confidence interval: 2.28-2.98) in 1990 to 4.58 (4.04-5.13) in 2021, and the prevalence gap from 20.17 (17.31-23.02) to 36.96 (32.26-41.65). During 2020-2045, incidence and prevalence numbers and ASRs are projected to increase annually. Although death ASRs are expected to decline, death counts will rise. In 2045, incident cases, prevalent cases, and deaths are projected to reach 449,910 (95% UI: 45,706-884,520), 3,295,386 (310,305-6,488,732), and 78,818 (27,472-130,171), respectively.
conclusionsGlobal TC burden increased during 1990-2021, mainly because of population growth and aging. High-SDI countries bear a disproportionate burden, and inequalities have widened. Rising cases and unequal distribution challenge TC control and management. These findings may inform public health policy and equitable resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.